title: A pharmacokinetic model of anaerobic in vitro carbon tetrachloride metabolism.
abstract: Carbon tetrachloride (CCl4) is a potent hepatotoxic agent whose toxicity is mediated through cytochome P450-dependent metabolism. Results from anaerobic in vitro experiments with hepatic microsomes isolated from male F-344 rats indicate that chlorofom (CHCl3) formation from CCl4 is nonlinear with dose. Dose is traditionally expressed as the amount of CCl4 added to the vial. In this study, a pharmacokinetic model has been developed to calculate the concentration of CCl4 in the microsomal suspension. Hepatic microsomes prepared from fed and fasted animals were incubated with CCl4 under anaerobic conditions and formation of CHCl3 over a 5-min incubation period was monitored by headspace gas chromatography. Dose-response curves, based on total amount of CCl4 added to the microsomes, revealed a nonlinear, biphasic appearance of CHCl3, with fasting slightly increasing CHCl3 production in microsomes prepared from fasted rats. Microsomes were also pretreated with the CYP2E1 inhibitor, diallyl sulfone (DAS), before addition of CCl4. In uninhibited microsomes, there appeared to be a high-affinity saturable phase of metabolism occurring at lower concentrations followed by a linear phase at higher CCl4 concentrations. Following DAS pretreatment, the saturable portion of the dose-response curve was inhibited more than the linear phase with the biphasic CHCl3 production becoming more linear. DAS inhibition eliminated the effect of fasting on CHCl3 formation. The best fit kinetic constants for the saturable phase resulted in an estimate of V(max) of 0.017 mg/h/mg protein (V(maxc) = 7.61 mg/h/kg) and Km of 2.3 mg/l (15 microM). The linear phase rate constant (kf) was determined to be 0.046 h-1) (kfc = 0.03 h-1). In conclusion, a pharmacokinetic model has been developed for anaerobic in vitro metabolism of CCl4 to CHCl3 that estimates metabolic rates based on CHCl3 formation and actual CCl4 concentration in the microsomal suspension.
authors.affiliation: Pharmacokinetics Branch (MD-74), United States Environmental Protection Agency, Research Triangle Park, NC 27711, USA.
authors.forename: N J
authors.initials: NJ
authors.lastname: Andersen
authors.forename: C L
authors.initials: CL
authors.lastname: Waller
authors.forename: J B
authors.initials: JB
authors.lastname: Adamovic
authors.forename: D J
authors.initials: DJ
authors.lastname: Thompson
authors.forename: J W
authors.initials: JW
authors.lastname: Allis
authors.forename: M E
authors.initials: ME
authors.lastname: Andersen
authors.forename: J E
authors.initials: JE
authors.lastname: Simmons
mesh_terms: D000498:Allyl Compounds / Q000494:pharmacology; D000693:Anaerobiosis; D000818:Animals; D002251:Carbon Tetrachloride / Q000378:metabolism / Q000493:pharmacokinetics*; D002725:Chloroform / Q000378:metabolism*; D019392:Cytochrome P-450 CYP2E1; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005215:Fasting; D005502:Food; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D008954:Models, Biological; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D013450:Sulfones / Q000494:pharmacology
chemical_list: D000498:Allyl Compounds; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D013450:Sulfones; C068327:diallyl sulfone; D002725:Chloroform; D003577:Cytochrome P-450 Enzyme System; D002251:Carbon Tetrachloride; D019392:Cytochrome P-450 CYP2E1; D010089:Oxidoreductases, N-Demethylating